Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Suresh S RamalingamLuis Paz-Ares

Abstract

The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are superior to the reversible inhibitors. Dacomitinib is an oral, small-molecule irreversible inhibitor of all enzymatically active HER family tyrosine kinases. The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067) studies randomized patients with locally advanced/metastatic NSCLC following progression with one or two prior chemotherapy regimens to dacomitinib or erlotinib. EGFR mutation testing was performed centrally on archived tumor samples. We pooled patients with exon 19 deletion and L858R EGFR mutations from both studies to compare the efficacy of dacomitinib to erlotinib. One hundred twenty-one patients with any EGFR mutation were enrolled; 101 had activating mutations in exon 19 or 21. For patients with exon19/21 mutations, the median progression-free survival was 14.6 months [95% confidence interval (CI) 9.0-18.2] with dacomitinib and 9.6 months (95% CI 7.4-12.7) with erlotinib [unstratified hazard ratio (HR) 0.717 (95% CI 0.458-1.124), two-sided log-rank, P = 0.146]. The median survival was 26.6 months (95% CI 21.6-41.5) with dacomitinib versus ...Continue Reading

References

Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J RielyVincent A Miller
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jul 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suresh S RamalingamMichael Boyer
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Apr 30, 2015·The New England Journal of Medicine·Pasi A JänneMalcolm Ranson
Apr 30, 2015·The New England Journal of Medicine·Lecia V SequistD Ross Camidge

❮ Previous
Next ❯

Citations

Dec 4, 2016·Hematology/oncology Clinics of North America·Suchita Pakkala, Suresh S Ramalingam
Jul 30, 2019·Expert Review of Clinical Pharmacology·Mariacarmela SantarpiaRafael Rosell
Jun 3, 2016·Oncotarget·Faheem Ahmed KhanZhang ShuJun
Jun 20, 2018·Drugs·Asunción Díaz-SerranoLuis Paz-Ares Rodríguez
Aug 22, 2018·Advanced Science·Seah Ling KuanTanja Weil
Dec 7, 2018·Drugs·Matt Shirley
Dec 21, 2017·Skin Pharmacology and Physiology·Ana R FernandesEliana B Souto
May 10, 2019·Drugs·Sally C M LauHerbert H Loong
Jan 27, 2019·Oncotarget·Xiaojuan AiShudong Zhu
Apr 3, 2020·Acta Pharmacologica Sinica·Xiao-Yun LiuDa-Fang Zhong
Nov 24, 2021·Molecular Diagnosis & Therapy·Barbara MeloskyFederico Cappuzzo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.